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ABSTRACT 1 
Background/Objectives: Phytoestrogen rich-foods such as soy may be associated with less 2 
frequent/severe vasomotor menopausal symptoms (VMS), although evidence is limited. We 3 
thus investigated the associations between the consumption of soy products and soy milk and 4 
the frequency/severity of VMS.  5 
Subjects/Methods: We pooled data from 19,351 middle-aged women from five 6 
observational studies in Australia, UK, USA, and Japan that contribute to the International 7 
Collaboration for a Life course Approach to reproductive health and Chronic disease Events 8 
(InterLACE). Information on soy consumption, VMS and covariates were collected by self-9 
report. We included 11,006 women who had complete data on soy consumption, VMS and 10 
covariates at baseline for the cross-sectional analysis. For the prospective analysis, 4,522 11 
women who were free of VMS at baseline and had complete data on VMS at follow-up were 12 
considered. Multinomial logistic regression and binary logistic regression models were used.  13 
Results: No statistically significant evidence of an association was found between soy 14 
products (relative risk ratio (RRR): 0.92, 95% CI: 0.761.11) or soy milk (RRR: 1.24, 95% 15 
CI: 0.931.65) and the likelihood of reporting frequent or severe VMS cross-sectionally. 16 
Prospective results indicated that frequent consumption of soy products (odds ratio (OR): 17 
0.63, 95% CI: 0.450.89) but not soy milk (OR: 1.11, 95% CI: 0.851.45) was associated 18 
with lower likelihood of reporting subsequent VMS, after adjustment for socio-demographic 19 
and reproductive factors. 20 
Conclusions: These are the first ever findings from pooled observational data of association 21 
between consumption of soy products and VMS.  22 
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INTRODUCTION 23 
Menopause, a natural event marking the end of the reproductive life of women, is often 24 
accompanied by menopausal symptoms. Vasomotor menopausal symptoms (VMS), including 25 
hot flushes and night sweats, are the most common symptoms which arise as a consequence 26 
of a decline in endogenous oestrogen levels, in particular during the perimenopausal and 27 
early postmenopausal phases [1, 2]. The frequency and severity of VMS usually decrease 28 
over time, but this varies by individual with symptoms subsiding after a year for some or 29 
persisting for over 30 years in others [3]. The frequency/severity of VMS have been linked to 30 
various chronic diseases including cardiovascular disease, osteoporosis, and cognitive decline 31 
[4, 5].  32 
Phytoestrogen rich-foods such as soy have been associated with less frequent and less severe 33 
menopausal symptoms, although evidence is limited [6, 7]. Epidemiological studies which 34 
investigated the association between soy intake and the frequency/severity of VMS also 35 
demonstrated conflicting results [8, 9]. Moreover, according to a review of 43 randomised 36 
controlled trials (RCTs) [1], the positive effect of phytoestrogen supplements on the 37 
frequency/severity of hot flushes and night sweats in peri- or post-menopausal women is still 38 
inconclusive given the small sample size and potential high risk of bias of the included trials. 39 
However, the same review suggested that the effect of genistein (a soy derived isoflavone) 40 
was promising [1].  41 
While dietary intake of phytoestrogens is usually in the form of soy bean, soy bean curd, tofu, 42 
tempeh, soy milk and other soy products, most studies have investigated the effects of soy 43 
supplements and extracts [10-12]. This study thus sought to elucidate the cross-sectional and 44 
prospective associations between soy intake and VMS among peri and post-menopausal 45 
women across five studies contributing to the International Collaboration for a Life course 46 
Approach to reproductive health and Chronic disease Events (InterLACE) consortium.  47 
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 48 
SUBJECTS AND METHODS 49 
Ethical approval 50 
Written consent was obtained from all participants. All the cohort studies included in the 51 
InterLACE consortium have been previously granted ethical approval by the respective 52 
ethical committees [13].  53 
Study participants 54 
The InterLACE consortium includes individual data from ten countries. It involves around 55 
230,000 participants from 20 observational studies with data on womens health (12 of which 56 
provide longitudinal data). Further detailed information on InterLACE has been published 57 
elsewhere [13, 14]. For the current study, five studies that had information on soy intake (the 58 
exposure) and hot flushes and/or night sweats (the outcome) were included: Australian 59 
Longitudinal Study on Women's Health (ALSWH) [15], Healthy Ageing of Women Study 60 
(HOW) − Australia, Whitehall II study (WHITEHALL) − UK [16], Seattle Midlife Womens 61 
Health Study (SMWHS) [17] and Japanese Midlife Womens Health Study (JMWHS) [18] 62 
(Supplementary Table 1). For the cross-sectional analysis, data from 11,006 women who 63 
reported VMS (either frequency or severity), consumption frequency of soy products and soy 64 
milk and had complete information on confounders (listed below) were included in the 65 
analysis. The prospective analysis included data from three studies (ALSWH, HOW and 66 
WHITEHALL) (n=10,082). Excluding 5,560 women who reported VMS at baseline and 67 
those with missing data on VMS, menopausal status, and use of hormone therapy at follow-68 
up, 4,522 women were considered for the prospective analysis (Supplementary Figure 1). 69 
 70 
Main outcome and exposure variables 71 
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VMS was defined as the presence of hot flushes and/ or night sweats. Response options for 72 
the frequency of hot flushes and night sweats (over the last 12 months) were never, rarely, 73 
sometimes, and often in ALSWH. For the other four studies, the severity of VMS over a 74 
shorter period was recorded; HOW, WHITEHALL and JMWHS considered the current 75 
severity of VMS, while SMWHS considered the severity of VMS in the last 1-3 months. For 76 
example, in HOW and JMWHS the response options for the extent of symptoms were not at 77 
all, a little, quite a bit, and extremely and for WHITEHALL the response options were not 78 
at all, a little, somewhat, and a lot. The degree of severity was harmonised as never, mild, 79 
moderate and severe over a shorter period of time. Since the frequency of VMS was assessed 80 
in ALSWH and severity in the remaining four studies, results were presented separately. 81 
VMS were further coded dichotomously as absent’ (never and rarely if reporting frequency; 82 
never and mild if reporting severity) and present (sometimes and often if reporting 83 
frequency; moderate and severe if reporting severity) for the study-specific and prospective 84 
analysis.  85 
Soy products such as tofu, soy beans, tempeh, and soy milk were commonly reported in the 86 
five studies. The soy products were combined based on their phytoestrogen contents. Thus, 87 
tofu, soy beans, tempeh, and soy flour having a high phytoestrogen content were grouped 88 
under the soy products category, while soy milk was considered separately [19, 20].  89 
In ALSWH, there were ten consumption frequency options: never, less than once per month, 90 
1-3 times per month, 1 time per week, 2 times per week, 3-4 times per week, 5-6 times per 91 
week, 1 time per day, 2 times per day, 3 or more times per day. In the WHITEHALL study, 92 
nine consumption frequency options were provided; five in SMWHS and four response 93 
categories in HOW and JMWHS. Therefore, for this study, studies having more than four 94 
categories were collapsed into four frequency categories: never/rarely, monthly, weekly, 95 
and daily. They were further coded dichotomously as less frequent (never/rarely and 96 
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monthly) and frequent (weekly and daily) given the small number of observations for 97 
weekly and daily intake for the prospective analysis.  98 
 99 
Covariates  100 
Categorical variables in the InterLACE study were collapsed into the simplest categories 101 
possible so as to include data from as many studies as possible [13]. For example, education 102 
level was collated into three categories as 10 years, 11-12 years, and >12 years. Smoking 103 
status was grouped as never smokers, past smokers, and current smokers. Based on 104 
gynaecological surgery and menstrual bleeding patterns, menopausal status was collated into 105 
five categories to include 1) hysterectomy/oophorectomy, 2) unknown due to hormone use 106 
(menopausal hormone therapy or oral contraceptive hormones before reaching menopause), 107 
3) premenopause (regular menstruation in the last 3 and 12 months), 4) perimenopause 108 
(menses in the past 3 months and changes/irregularity in menstrual patterns in the past 12 109 
months; or no menses in the previous 3 months but menses in the preceding 11 months), and 110 
5) natural postmenopause (amenorrhea for at least 12 months). Current use of menopausal 111 
hormone therapy (e.g. oestrogen) was categorised as yes and no.  112 
 113 
Statistical analysis 114 
As the result of different assessments (frequency or severity) and different recall periods (in 115 
the past 12 months or in a more recent period) for VMS, studies were grouped as: 1) 116 
frequency of VMS in the past 12 months (ALSWH); 2) severity of VMS over a shorter time 117 
period (HOW, WHITEHALL, SMWHS, and JMWHS). The associations between soy 118 
consumption and VMS were first examined separately for the two different designs, followed 119 
by the overall estimates.  120 
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Multinomial logistic regression models with four categories of outcome for VMS (never, 121 
rarely/mild, sometimes/moderate, and often/severe) were used to investigate the cross-122 
sectional associations between frequency of consumption of soy products and soy milk with 123 
frequency/severity of VMS at baseline. The VMS category never was used as the reference 124 
group for the outcome, and the soy consumption category never was used as the reference 125 
group for the exposure. Relative risk ratios (RRR) and 95% confidence intervals (CI) were 126 
estimated. According to the minimally sufficient set of adjustments, smoking status, 127 
education level, menopausal status, and race/ethnicity were identified as confounders using a 128 
directed acyclic graph (Supplementary Figure 2) and were adjusted for in the regression 129 
models. However, race/ethnicity was not included in the model as participants from ALSWH 130 
(96.5%), HOW (95.1%), WHITEHALL (88.1%) and SMWHS (88.1%) were mainly 131 
Caucasians, and in JMWHS all the participants were Japanese. Concurrent menopausal 132 
hormone therapy use was included in the model given its potential effect on the 133 
frequency/severity of VMS [21]. The models were thus adjusted for menopausal status and 134 
concurrent menopausal hormone therapy use (model 1) and additionally adjusted for other 135 
potential covariates including education level and smoking status (model 2). Study was 136 
included as a fixed effect to account for differences in levels of VMS between studies and as 137 
a stratification variable to account for correlation of individuals within studies. 138 
Due to small numbers of participants in the four categories of exposure and outcome in 139 
individual studies, dichotomised soy consumption (frequent and less frequent) and 140 
dichotomised VMS (presence and absence) were used for the study-specific and prospective 141 
analysis. To examine between-study heterogeneity in the effect size estimates, study-specific 142 
logistic regression and random-effects meta-analysis were used with the estimates adjusted 143 
for all the covariates in model 2.  144 
8 
 
 
For the prospective analysis based on three studies ( ALSWH, HOW and WHITEHALL), 145 
logistic regression models with the binary outcome for VMS (presence and absence) were 146 
fitted, adjusted for all the covariates in model 2. In addition, a sensitivity analysis was 147 
conducted to investigate the association between soy consumption and subsequent risk of 148 
VMS at follow-up with all the women included (n=10,082), but adjusting for their baseline 149 
VMS, given that a large proportion of women were excluded in the prospective analysis due 150 
to the presence of VMS at baseline. Analyses were performed using STATA 14 (StataCorp 151 
LP, College Station, Texas). All statistical tests were two sided. 152 
 153 
RESULTS 154 
11,006 women reported their consumption frequency of soy and VMS, and also had complete 155 
data on the covariates. The median age of the women at baseline was 52 years (interquartile 156 
range: 51-54) (Supplementary Table 1). Table 1 shows the baseline characteristics of the 157 
participants in each study. The majority of the participants were Caucasians-158 
Australians/New-Zealanders (57.5%), had 10 years or less of education (46.3%), and never 159 
smoked (60.9%). Nearly 30% of the women were naturally postmenopausal, and 26.5% were 160 
currently using menopausal hormone therapy. Across HOW, WHITEHALL, SMWHS, and 161 
JMWHS which measured the severity of VMS, WHITEHALL had the highest percentage of 162 
women who reported severe VMS (11.1%), while JMWHS (Japanese) had the lowest 163 
percentage (4.4%). In the ALSWH study, 24.6% reported often for the frequency of VMS. 164 
In this predominantly Caucasian population, 80-90% of the women reported that they never 165 
consumed soy products or soy milk. Across the individual studies, JMWHS had the largest 166 
percentage of women who reported daily and weekly soy product consumption (49.3% 167 
and 47.7% respectively) (Table 1). Comparing baseline characteristics of women included in 168 
the prospective analysis and those excluded due to loss to follow-up, the excluded women 169 
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were less educated and more likely to be obese and current smokers at baseline. They were 170 
more likely to be postmenopausal and less likely to report frequent/severe VMS compared to 171 
women with complete follow-up data (Supplementary Table 2). 172 
For the cross-sectional analysis, women with weekly and daily consumption of soy 173 
products were less likely to report frequent/severe VMS compared with those with 174 
never/rarely consumption (11.7 vs. 20.5% and 6.4 vs. 20.5%, respectively) (Table 2). 175 
However, after adjusting for covariates and study differences, no clear evidence of an 176 
association was found between soy product consumption and the degree of VMS. Similarly, 177 
there was no clear evidence of an association observed for ALSWH or the other four studies. 178 
For soy milk consumption, women with a daily consumption were more likely to report 179 
frequent/severe VMS compared to women who reported never/rarely consumption (RRR: 180 
1.56, 95% CI: 1.241.96). A similar pattern for daily consumption and risk of 181 
frequent/severe VMS was observed in ALSWH (RRR: 1.39, 95% CI: 1.101.77) and the 182 
other four studies (RRR: 3.09, 95% CI: 1.476.50).  183 
When using dichotomised exposure and outcome variables for the study-specific analysis, the 184 
pooled estimate of association between frequent soy product consumption and the presence of 185 
VMS was OR: 0.92, 95% CI: 0.761.11, with no statistically significant heterogeneity 186 
between studies, test for heterogeneity: P = 0.49, I
2
 = 0% (Figure 1). For the association 187 
between frequent consumption of soy milk and the presence of VMS, the pooled OR estimate 188 
was 1.24 (95% CI: 0.931.65) with no statistically significant heterogeneity between the 189 
studies (test for heterogeneity: P = 0.24, I
2
 = 26.6%) (Figure 2).  190 
For the prospective analysis, the overall estimates suggest that women with frequent soy 191 
product consumption were less likely to report the incidence of VMS at follow-up (OR: 0.63, 192 
95% CI: 0.450.89) (Table 3).  A consistent pattern was observed in ALSWH (OR: 0.63, 193 
95% CI: 0.440.90) and the other four studies (OR: 0.60, 95% CIĻġ0.181.97). There was no 194 
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clear evidence of an association between frequent consumption of soy milk and incident 195 
VMS at follow-up (OR: 1.11, 95% CI: 0.851.45). The sensitivity analysis with all the 196 
women included demonstrated a similar or weaker association between soy consumption and 197 
subsequent VMS, even adjusted by baseline VMS (Table 4).  198 
 199 
DISCUSSION 200 
This pooled study demonstrated no clear evidence of an association between consumption 201 
frequency of soy products and VMS in the cross-sectional analysis. However, in the 202 
prospective analysis, women with frequent consumption of soy products were less likely to 203 
report subsequent VMS. Furthermore, there was no evidence of an association between 204 
consumption of soy milk and frequency/severity of VMS both cross-sectionally (Figure 1, 2) 205 
and prospectively (Table 3).   206 
Our prospective analysis showed an association between frequent consumption of soy 207 
products and decreased odds of VMS at follow-up, though this was attenuated when baseline 208 
VMS was taken into account. Similarly, a Japanese community-based study in which women 209 
were followed for six years found that soy products intake alleviated hot flushes [9]. Several 210 
RCTs have investigated the association between some type of substance containing dietary 211 
soy (e.g. soy extract in capsule or tablet form, soy powder or soy protein added to diets) and 212 
its effect on hot flushes. While some demonstrated a reduction in the frequency/severity of 213 
hot flushes [10, 22-24], others have shown contradictory findings [25, 26]. According to a 214 
review study, the dose of genistein, in particular, was associated with a reduction of the 215 
symptoms rather than total isoflavone [27]. The oestrogen-like properties of soy food due to 216 
the isoflavones content have been linked to the protective effect on VMS. A decrease in the 217 
number of ovarian follicles and consequent fall in oestrogen level could be the underlying 218 
hormonal aetiology of VMS [28, 29]. However, the effect of phytoestrogens in reducing 219 
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VMS remains unclear [30]. One of the possible mechanism of action is the structural 220 
similarity of isoflavones to that of oestradiol could confer oestrogenic or anti-oestrogenic 221 
effects depending on the circulating oestrogen level by binding to oestrogen receptors [31, 222 
32]. The relative decline in oestrogen level leads to higher circulating norepinephrine levels 223 
and an upregulation of serotonin receptors which mediate hot flushes in menopausal women. 224 
By binding to oestrogen receptors, isoflavones help to restore the oestrogen level, and causes 225 
subsequent changes in norepinephrine and serotonin levels, thus reducing the propensity of 226 
hot flushes [33]. 227 
Our pooled data did not show a clear association between soy milk consumption and 228 
frequency/severity of VMS. The source of dietary isoflavones may also contribute to the 229 
observed effect since processing methods tend to alter the phytoestrogen contents of soy 230 
products [34]. For instance, the total isoflavone content in soy beans (103mg per 100g), 231 
tempeh (18mg per 100g) and tofu (27mg per 100g) is much higher than that in soy milk (3mg 232 
per 100g) [20]. The overall low consumption frequency of soy milk among the participants 233 
and its low isoflavone content could possibly explain this finding. 234 
The main drawback of our study is the variation in assessments used by the different studies. 235 
Soy consumption was measured as frequency, with no information on quantities. Moreover, 236 
for the consumption of soy milk, the cross-sectional nature of some of the studies and lack of 237 
evidence of a significant association from the prospective analysis, mean that we cannot 238 
confirm a temporal relationship between soy milk consumption and VMS. There also might 239 
be possibility of residual confounding, e.g. by factors not measured in the studies. One 240 
weakness of data harmonisation is the collapsing of the variables of interest into the simplest 241 
level of detail in order to incorporate information from as many studies as possible, leading to 242 
loss of statistical power as well as potential misclassification of the degree of VMS and 243 
frequency of soy consumption. For instance, studies like ALSWH and WHITEHALL had ten 244 
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and nine frequency options respectively for consumption of soy that were collapsed to four 245 
categories for this analysis. In addition, the frequency of VMS was reported in ALSWH over 246 
a longer period of time (12 months), and the other four studies recorded the severity of VMS 247 
over a shorter period that limited our ability to pool data. Despite these limitations the pooled 248 
results showed considerable homogeneity as shown in the forest plots and the low values for 249 
the statistic I
2
. 250 
Furthermore, our study had several strengths that ranged from the inclusion of a large number 251 
of women across different geographic regions and cultures that allowed greater 252 
generalisability of the results. This is also, to our knowledge, the first pooled study consisting 253 
of womens health studies from four different countries examining an association between 254 
soy products and soy milk with frequency/severity of VMS. We also included women who 255 
had a hysterectomy, oophorectomy, and/or were currently using hormones that could provide 256 
a better estimate of the prevalence of VMS. In addition, the individual data available in the 257 
InterLACE enabled harmonization of the variables of interest using common definitions, 258 
coding and cut points not normally possible with meta-analyses of published results. 259 
Harmonisation of the data further reduces the between-study heterogeneity. A consistent 260 
approach to confounder adjustment was used for the regression models along with careful 261 
selection of the confounders using a DAG, thus reducing the probability of the results being 262 
affected by uncontrolled confounders.  263 
While menopause is an inevitable phenomenon in a womans life cycle, the frequency and 264 
severity of VMS show marked variations [35]. VMS are reported by around 75% of 265 
postmenopausal women globally, with a minority reporting severe symptoms [36, 37]. 266 
Findings from this study provide some evidence that frequent consumption of soy products 267 
(e.g., soy beans, tofu, tempeh) as part of the usual diet may be associated with a reduced risk 268 
of subsequent VMS. However, frequent consumption of soy milk did not appear to be 269 
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associated with subsequent VMS. As justified by potential mechanisms in previous studies, 270 
our findings could prompt RCTs testing the effects of dietary soy intake in particular on VMS 271 
as opposed to earlier RCTs which have mainly considered the effects of soy extracts and 272 
supplements. 273 
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Figure 1. Forest plot of study-specific effect estimates of the cross-sectional association between consumption 
frequency of soy products and the presence of vasomotor menopausal symptoms at baseline. Soy product 
consumption was coded dichotomously as frequent (weekly and daily) and less frequent (never/rarely and 
monthly) and vasomotor symptoms as present (sometimes and often if reporting frequency; moderate and 
severe if reporting severity) and absent’ (never and rarely if reporting frequency; never and mild if reporting 
severity) given the small number of observations in each study. Odds ratios (ORs) a presented on a log scale. 
Effect estimates were adjusted for menopausal status, current use of menopausal hormone therapy, education 
level, and smoking status. VMS: Vasomotor menopausal symptoms 
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Figure 2. Forest plot of study-specific effect estimates of the cross-sectional association between consumption 
frequency of soy milk and the presence of vasomotor menopausal symptoms at baseline. Soy milk consumption 
was coded dichotomously as frequent (weekly and daily) and less frequent (never/rarely and monthly) and 
vasomotor symptoms as present (sometimes and often if reporting frequency; moderate and severe if reporting 
severity) and absent’ (never and rarely if reporting frequency; never and mild if reporting severity) given the 
small number of observations in each study. Odds ratios (ORs) a presented on a log scale. Effect estimates were 
adjusted for menopausal status, current use of menopausal hormone therapy, education level, and smoking 
status. VMS: Vasomotor menopausal symptoms 
 
 
 
